In a previous report, we identified two genes, RPL39 (ribosomal protein L39) and MLF2 (myeloid leukemia factor 2), that are commonly mutated in lung metastases from breast cancer patients, and their inhibition significantly reduced BCSC self-renewal and number, tumor cell migration, invasion and generation of lung metastases, and tumor growth in in vitro and patient-derived xenografts (PDX) models of TNBC. This evidence concerns the gene MLF2 and breast carcinoma.